Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (1-10 of 387) with videos related to

Pageof 39
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|March 27, 2004
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphomaThomas E Witzig
Best Practice & Research. Clinical Haematology|September 26, 2006
Radioimmunotherapy for B-cell non-Hodgkin lymphomaThomas E Witzig
Seminars in Oncology|January 8, 2004
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphomaThomas E Witzig
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2005
Current treatment approaches for mantle-cell lymphomaThomas E Witzig
Hematology/Oncology Clinics of North America|August 31, 2020
What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?Thomas E Witzig
Blood|April 11, 2019
Acalabrutinib for mantle cell lymphomaThomas E Witzig, David Inwards
Hematology. American Society of Hematology. Education Program|January 18, 2011
Signal transduction inhibitor therapy for lymphomaThomas E Witzig, Mamta Gupta
Current Treatment Options in Oncology|June 21, 2002
Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphomaThierry Alcindor, Thomas E Witzig
Clinical Advances in Hematology & Oncology : H&O|May 27, 2006
Radioimmunotherapy for B-cell non-Hodgkin lymphomaGrzegorz S Nowakowski, Thomas E Witzig
Current Treatment Options in Oncology|August 19, 2006
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignanciesThomas E Witzig, Scott H Kaufmann
Pageof 39

Showing results (1-10 of 387) with videos related to

Sort By:
Pageof 39
Drugs of Today (Barcelona, Spain : 1998)|March 27, 2004
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphomaThomas E Witzig
Best Practice & Research. Clinical Haematology|September 26, 2006
Radioimmunotherapy for B-cell non-Hodgkin lymphomaThomas E Witzig
Seminars in Oncology|January 8, 2004
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphomaThomas E Witzig
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2005
Current treatment approaches for mantle-cell lymphomaThomas E Witzig
Hematology/Oncology Clinics of North America|August 31, 2020
What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?Thomas E Witzig
Blood|April 11, 2019
Acalabrutinib for mantle cell lymphomaThomas E Witzig, David Inwards
Hematology. American Society of Hematology. Education Program|January 18, 2011
Signal transduction inhibitor therapy for lymphomaThomas E Witzig, Mamta Gupta
Current Treatment Options in Oncology|June 21, 2002
Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphomaThierry Alcindor, Thomas E Witzig
Clinical Advances in Hematology & Oncology : H&O|May 27, 2006
Radioimmunotherapy for B-cell non-Hodgkin lymphomaGrzegorz S Nowakowski, Thomas E Witzig
Current Treatment Options in Oncology|August 19, 2006
Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignanciesThomas E Witzig, Scott H Kaufmann
Pageof 39